| 211 |
Higher proportion of non-classical and intermediate monocytes in newly diagnosed multiple myeloma patients in Egypt: a possible prognostic marker
|
Department of Clinical Pathology |
2021 |
| 212 |
HLA-B* 15 predicts survival in Egyptian patients with COVID-19 |
Department of Clinical Pathology |
2021 |
| 213 |
Increase in polymorphonuclear myeloid‑derived suppressor cells and regulatory T‑cells in children with B‑cell acute lymphoblastic leukemia |
Department of Pediatric Oncology |
2021 |
| 214 |
Interleukin-10: A Potential Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma |
Department of Clinical Pathology |
2021 |
| 215 |
Interleukin-10: A Potential Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma |
Department of Clinical Pathology |
2021 |
| 216 |
Interleukin-10: A Potential Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma |
Department of Clinical Pathology |
2021 |
| 217 |
Interleukin-10: A Potential Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma |
Department of Medical Oncology |
2021 |
| 218 |
Interleukin-10: A Potential Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma |
Department of Medical Oncology |
2021 |
| 219 |
Interleukin-10: A Potential Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma |
Department of Medical Oncology |
2021 |
| 220 |
Interleukin-10: A Potential Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma |
Department of Clinical Pathology |
2021 |
